Kim Youn Ho, Han Woo Sik, Lee Sun Jae, Oh Sung Nam, Choi Do Won, Byun Kwan Soo, Yeon Jong Eun
Department of Internal Medicine, Korea University Medical College, Guro Hospital, Seoul, Korea.
Korean J Hepatol. 2007 Sep;13(3):419-22. doi: 10.3350/kjhep.2007.13.3.419.
There has been an increase in the number of patients treated with pegylated interferon (PEG-IFN) and ribavirin due to the better antiviral efficacy. The main serious adverse events of PEG-IFN plus ribavirin combination therapy are bone marrow suppression and hemolytic anemia. However, there are few reports of vasculitis occurring during PEG-IFN therapy. We describe a patient who developed vasculitis during the treatment of chronic hepatitis C with PEG-IFN and ribavirin.
由于聚乙二醇干扰素(PEG-IFN)和利巴韦林具有更好的抗病毒疗效,接受其治疗的患者数量有所增加。PEG-IFN加利巴韦林联合治疗的主要严重不良事件是骨髓抑制和溶血性贫血。然而,关于PEG-IFN治疗期间发生血管炎的报道很少。我们描述了一名在使用PEG-IFN和利巴韦林治疗慢性丙型肝炎期间发生血管炎的患者。